An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With PSMA Positive Recurrent or Progressive Glioblastoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Mipsagargin (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Inspyr Therapeutics
- 22 Feb 2017 Planned initiation date changed from 1 Oct 2016 to 1 Sep 2016.
- 22 Feb 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 25 Sep 2016 Status changed from not yet recruiting to recruiting.